Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open-label study extension of the SALIVA trial.

Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16268 Proveca Ltd In participants initially on placebo who switched to 320 μg/mL glycopyrronium for the OLSE, the median change in total DIS score between day 84 and day 252 of −18 points was highly significant (−44, −5; p < 0.001) (Table 3 ).

also in 132,142 other papers